Muzastotug Combination Therapy Shows Significant Efficacy in Liver Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy ADAG?
Source: Newsfilter
- Significant Efficacy Improvement: In a Phase 1b/2 trial for locally advanced or metastatic hepatocellular carcinoma (HCC), the triple combination of muzastotug with atezolizumab and bevacizumab achieved a 66.7% overall response rate, markedly higher than the 32.5% in the control arm, indicating substantial potential for enhanced treatment outcomes.
- Good Safety Profile: The triple regimen demonstrated a safety profile comparable to historical studies of the doublet, with 50% of patients experiencing grade 3 or higher treatment-related adverse events, supporting the continuous dosing of muzastotug and potentially offering better tolerability for patients.
- Dose-Dependent Response: In a Phase 1b/2 trial for microsatellite stable colorectal cancer, the combination of muzastotug with pembrolizumab and fruquintinib exhibited response rates of 25% and 40% at doses of 10 mg/kg and 15 mg/kg, respectively, highlighting the regimen's efficacy across different dosing levels.
- FDA Fast Track Designation: The combination of muzastotug with KEYTRUDA has received FDA Fast Track designation, underscoring its potential in treating microsatellite stable metastatic colorectal cancer and further advancing Adagene's strategic development in cancer immunotherapy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADAG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADAG
Wall Street analysts forecast ADAG stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.780
Low
8.00
Averages
8.50
High
9.00
Current: 3.780
Low
8.00
Averages
8.50
High
9.00
About ADAG
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Muzastotug Combination Therapy Shows Significant Efficacy in Liver Cancer Treatment
- Significant Efficacy Improvement: In a Phase 1b/2 trial for locally advanced or metastatic hepatocellular carcinoma (HCC), the triple combination of muzastotug with atezolizumab and bevacizumab achieved a 66.7% overall response rate, markedly higher than the 32.5% in the control arm, indicating substantial potential for enhanced treatment outcomes.
- Good Safety Profile: The triple regimen demonstrated a safety profile comparable to historical studies of the doublet, with 50% of patients experiencing grade 3 or higher treatment-related adverse events, supporting the continuous dosing of muzastotug and potentially offering better tolerability for patients.
- Dose-Dependent Response: In a Phase 1b/2 trial for microsatellite stable colorectal cancer, the combination of muzastotug with pembrolizumab and fruquintinib exhibited response rates of 25% and 40% at doses of 10 mg/kg and 15 mg/kg, respectively, highlighting the regimen's efficacy across different dosing levels.
- FDA Fast Track Designation: The combination of muzastotug with KEYTRUDA has received FDA Fast Track designation, underscoring its potential in treating microsatellite stable metastatic colorectal cancer and further advancing Adagene's strategic development in cancer immunotherapy.
See More
Adagene Appoints New Advisory Board Member
- New Member Addition: Adagene has announced the appointment of Dr. Peter Lebowitz to its Scientific and Strategic Advisory Board, whose extensive experience in expediting breakthrough therapies is expected to enhance the clinical development of ADG126, particularly in strategic planning for registration studies.
- Technological Innovation: Lebowitz highlighted the innovative nature of Adagene's SAFEbody technology in CTLA-4 targeted therapies, enabling tumor-selective activation of ADG126 and precise depletion of regulatory T cells in the tumor microenvironment, demonstrating promising clinical activity in late-line MSS CRC patients.
- Industry Experience: Previously, Lebowitz served as the Global Head of Oncology R&D at Johnson & Johnson, where he successfully brought 13 new drugs to market with over 60 approvals, and his innovative approach to drug development will provide valuable insights and strategic guidance for Adagene.
- Future Outlook: Adagene is committed to developing novel antibodies to address globally unmet patient needs through its Dynamic Precision Library platform, and Lebowitz's addition is expected to further enhance the company's R&D capabilities and market competitiveness.
See More
Adagene Prices $70M Public Offering of ADSs
- Offering Pricing: Adagene announced the pricing of 18.67 million American depositary shares (ADSs) at $3.75 each, with expected gross proceeds of approximately $70 million, demonstrating the company's ability to raise capital in the market.
- Investor Participation: The offering attracted participation from both new and existing investors, including Janus Henderson Investors, Deerfield Management, and Columbia Threadneedle Investments, indicating strong market confidence and support for Adagene.
- Closing Timeline: The public offering is expected to close on April 6, 2026, reflecting the company's proactive planning for future funding needs aimed at supporting its business growth.
- Market Reaction: Following the announcement of the offering, Adagene's stock price rose 12.03% in pre-market trading to $4.0552, showcasing a positive investor response to the financing activity.
See More
Adagene Announces $70 Million Public Offering Pricing
- Stock Price Plunge: Adagene Inc. (ADAG) shares fell nearly 13% in pre-market trading on Thursday, reflecting negative market sentiment following the company's latest announcements, particularly regarding the public offering pricing.
- Public Offering Pricing: The company priced its $70 million public offering at $3.75 per ADS, representing a nearly 19% discount from Wednesday's closing price, indicating investor concerns about the company's future prospects.
- Clinical Trial Update: Adagene also provided an update on the Phase 1b/2 study of Muzastotug in combination with Keytruda for patients with microsatellite stable colorectal cancer, revealing improved durability of response among trial participants, potentially offering new hope for future treatments.
- Bearish Market Sentiment: Retail sentiment on Stocktwits around Adagene trended in the 'bearish' territory, suggesting a lack of confidence among investors regarding the company's future performance, which could further impact its stock price trajectory.
See More
Adagene Prices Public Offering, Stock Drops 14%
- Stock Price Decline: Adagene's stock fell approximately 14% during pre-market trading on Thursday, reflecting market concerns over its pricing, as the public offering was set at $3.75 per ADS, below its 30-day volume-weighted average price, which may impact investor confidence.
- Fundraising Goals: The public offering aims to raise approximately $70 million in gross proceeds by offering around 18.67 million ADSs, with each ADS representing 1.25 ordinary shares, and the funds will be used to support the development of its antibody-based cancer immunotherapy pipeline.
- Investor Participation: The offering attracted participation from both new and existing investors, including Janus Henderson Investors, Deerfield Management, Invus, Sirenia, and Columbia Threadneedle Investments, indicating market confidence and support for Adagene's future growth.
- Use of Proceeds: Adagene plans to utilize the funds raised to advance its clinical development and regulatory activities for its antibody-based cancer immunotherapy, aiming to accelerate product launch timelines and enhance its competitiveness in the biopharmaceutical sector.
See More
Adagene Prices Public Offering to Raise $70 Million
- Offering Size: Adagene has announced a public offering of 18.67 million American depositary shares at $3.75 each, expected to raise approximately $70 million in gross proceeds, reflecting strong market confidence in its antibody therapies.
- Investor Participation: The offering attracted participation from both new and existing investors, including Janus Henderson and Deerfield Management, indicating market recognition and support for Adagene's future growth, which may strengthen its capital base.
- Offering Arrangement: The public offering is being managed by Leerink Partners and LifeSci Capital, with an expected closing date of April 6, 2026, further solidifying Adagene's financing capabilities in the biotechnology sector.
- Strategic Implications: This financing will enable Adagene to accelerate the development of its antibody-based cancer immunotherapies, leveraging the raised funds to commercialize its innovative technologies and enhance its competitive position in the market.
See More
Muzastotug Combination Therapy Shows Significant Efficacy in Liver Cancer Treatment
- Significant Efficacy Improvement: In a Phase 1b/2 trial for locally advanced or metastatic hepatocellular carcinoma (HCC), the triple combination of muzastotug with atezolizumab and bevacizumab achieved a 66.7% overall response rate, markedly higher than the 32.5% in the control arm, indicating substantial potential for enhanced treatment outcomes.
- Good Safety Profile: The triple regimen demonstrated a safety profile comparable to historical studies of the doublet, with 50% of patients experiencing grade 3 or higher treatment-related adverse events, supporting the continuous dosing of muzastotug and potentially offering better tolerability for patients.
- Dose-Dependent Response: In a Phase 1b/2 trial for microsatellite stable colorectal cancer, the combination of muzastotug with pembrolizumab and fruquintinib exhibited response rates of 25% and 40% at doses of 10 mg/kg and 15 mg/kg, respectively, highlighting the regimen's efficacy across different dosing levels.
- FDA Fast Track Designation: The combination of muzastotug with KEYTRUDA has received FDA Fast Track designation, underscoring its potential in treating microsatellite stable metastatic colorectal cancer and further advancing Adagene's strategic development in cancer immunotherapy.
See More
Adagene Appoints New Advisory Board Member
- New Member Addition: Adagene has announced the appointment of Dr. Peter Lebowitz to its Scientific and Strategic Advisory Board, whose extensive experience in expediting breakthrough therapies is expected to enhance the clinical development of ADG126, particularly in strategic planning for registration studies.
- Technological Innovation: Lebowitz highlighted the innovative nature of Adagene's SAFEbody technology in CTLA-4 targeted therapies, enabling tumor-selective activation of ADG126 and precise depletion of regulatory T cells in the tumor microenvironment, demonstrating promising clinical activity in late-line MSS CRC patients.
- Industry Experience: Previously, Lebowitz served as the Global Head of Oncology R&D at Johnson & Johnson, where he successfully brought 13 new drugs to market with over 60 approvals, and his innovative approach to drug development will provide valuable insights and strategic guidance for Adagene.
- Future Outlook: Adagene is committed to developing novel antibodies to address globally unmet patient needs through its Dynamic Precision Library platform, and Lebowitz's addition is expected to further enhance the company's R&D capabilities and market competitiveness.
See More
Adagene Prices $70M Public Offering of ADSs
- Offering Pricing: Adagene announced the pricing of 18.67 million American depositary shares (ADSs) at $3.75 each, with expected gross proceeds of approximately $70 million, demonstrating the company's ability to raise capital in the market.
- Investor Participation: The offering attracted participation from both new and existing investors, including Janus Henderson Investors, Deerfield Management, and Columbia Threadneedle Investments, indicating strong market confidence and support for Adagene.
- Closing Timeline: The public offering is expected to close on April 6, 2026, reflecting the company's proactive planning for future funding needs aimed at supporting its business growth.
- Market Reaction: Following the announcement of the offering, Adagene's stock price rose 12.03% in pre-market trading to $4.0552, showcasing a positive investor response to the financing activity.
See More
Adagene Announces $70 Million Public Offering Pricing
- Stock Price Plunge: Adagene Inc. (ADAG) shares fell nearly 13% in pre-market trading on Thursday, reflecting negative market sentiment following the company's latest announcements, particularly regarding the public offering pricing.
- Public Offering Pricing: The company priced its $70 million public offering at $3.75 per ADS, representing a nearly 19% discount from Wednesday's closing price, indicating investor concerns about the company's future prospects.
- Clinical Trial Update: Adagene also provided an update on the Phase 1b/2 study of Muzastotug in combination with Keytruda for patients with microsatellite stable colorectal cancer, revealing improved durability of response among trial participants, potentially offering new hope for future treatments.
- Bearish Market Sentiment: Retail sentiment on Stocktwits around Adagene trended in the 'bearish' territory, suggesting a lack of confidence among investors regarding the company's future performance, which could further impact its stock price trajectory.
See More
Adagene Prices Public Offering, Stock Drops 14%
- Stock Price Decline: Adagene's stock fell approximately 14% during pre-market trading on Thursday, reflecting market concerns over its pricing, as the public offering was set at $3.75 per ADS, below its 30-day volume-weighted average price, which may impact investor confidence.
- Fundraising Goals: The public offering aims to raise approximately $70 million in gross proceeds by offering around 18.67 million ADSs, with each ADS representing 1.25 ordinary shares, and the funds will be used to support the development of its antibody-based cancer immunotherapy pipeline.
- Investor Participation: The offering attracted participation from both new and existing investors, including Janus Henderson Investors, Deerfield Management, Invus, Sirenia, and Columbia Threadneedle Investments, indicating market confidence and support for Adagene's future growth.
- Use of Proceeds: Adagene plans to utilize the funds raised to advance its clinical development and regulatory activities for its antibody-based cancer immunotherapy, aiming to accelerate product launch timelines and enhance its competitiveness in the biopharmaceutical sector.
See More
Adagene Prices Public Offering to Raise $70 Million
- Offering Size: Adagene has announced a public offering of 18.67 million American depositary shares at $3.75 each, expected to raise approximately $70 million in gross proceeds, reflecting strong market confidence in its antibody therapies.
- Investor Participation: The offering attracted participation from both new and existing investors, including Janus Henderson and Deerfield Management, indicating market recognition and support for Adagene's future growth, which may strengthen its capital base.
- Offering Arrangement: The public offering is being managed by Leerink Partners and LifeSci Capital, with an expected closing date of April 6, 2026, further solidifying Adagene's financing capabilities in the biotechnology sector.
- Strategic Implications: This financing will enable Adagene to accelerate the development of its antibody-based cancer immunotherapies, leveraging the raised funds to commercialize its innovative technologies and enhance its competitive position in the market.
See More
